RxDoctor Payments Data

Ngai Nguyen, MD

Cardiovascular Disease · San Jose, CANPI 1205883501

Payments from drug & device makers

$4,074in general payments, 2019–2025

Across 147 payments — averaging $27.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Novartis$368
  • Biotronik Inc.$341
  • Boston Scientific$314
  • Boehringer Ingelheim$241
  • Amarin Pharma, Inc.$241
  • plus $1K from 13 others

What the payments were for

  • Grants$1,12328%
  • Food & beverage$2,25055%
  • Education$70017%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,074 in reported general payments places this provider in the 55th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$425,204
Medicare patients
583
Services billed
2,971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban230$234,893
JardianceEmpagliflozin155$174,550
VascepaIcosapent Ethyl207$150,627
XareltoRivaroxaban155$139,758
ProliaDenosumab68$114,428
EntrestoSacubitril/Valsartan90$108,425
FarxigaDapagliflozin Propanediol79$76,244
Icosapent Ethyl157$54,965
TrulicityDulaglutide34$51,695
BrilintaTicagrelor82$47,267
OzempicSemaglutide26$35,217
TradjentaLinagliptin37$29,682
Repatha SureclickEvolocumab29$29,127
ZenpepLipase/Protease/Amylase18$22,273
JanuviaSitagliptin Phosphate23$19,723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$241$219,343223 claims
Johnson & JohnsonXarelto$37$139,758155 claims
AstraZenecaFarxiga, Brilinta$211$123,511161 claims
AmgenProlia$161$114,42868 claims
NovartisEntresto$368$108,42590 claims
Novo NordiskOzempic, Rybelsus$18$53,11741 claims
MerckJanuvia$152$19,72323 claims
BayerKerendia$136$8,78712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →